Precigen and Recurrent Respiratory Papillomatosis Foundation to Host the 2025 International RRP Awareness Day on June 11th
Precigen (PGEN) and the Recurrent Respiratory Papillomatosis Foundation (RRPF) announced they will co-host the annual RRP Awareness Day on June 11, 2025, in Washington DC. The international event aims to raise awareness about recurrent respiratory papillomatosis (RRP), a rare chronic disease affecting both children and adults.
RRP, mainly caused by HPV 6/11 infection, leads to papilloma growth in respiratory tracts, causing voice disturbance, compromised airways, and potential post-obstructive pneumonias. The disease affects approximately 27,000 adult patients in the US and over 125,000 patients globally. Currently, there is no FDA-approved treatment, with patients requiring multiple surgeries throughout their lifetime.
The event will feature an in-person panel discussion with patients, caregivers, and physicians, broadcast globally via webcast. It will focus on patient experiences, disease burden, and the need for new treatment options. Interested participants can register at www.RRPAwareness.org.
Precigen (PGEN) e la Recurrent Respiratory Papillomatosis Foundation (RRPF) hanno annunciato che co-organizzeranno la giornata annuale RRP Awareness Day l'11 giugno 2025 a Washington DC. L'evento internazionale ha l'obiettivo di sensibilizzare sul tema della papillomatosi respiratoria ricorrente (RRP), una malattia cronica rara che colpisce sia bambini che adulti.
La RRP, principalmente causata dall'infezione da HPV 6/11, provoca la crescita di papillomi nelle vie respiratorie, causando disturbi della voce, ostruzione delle vie aeree e potenziali polmoniti post-ostruttive. La malattia interessa circa 27.000 adulti negli Stati Uniti e oltre 125.000 pazienti a livello globale. Attualmente non esiste un trattamento approvato dalla FDA e i pazienti necessitano di numerosi interventi chirurgici nel corso della vita.
L'evento prevede una tavola rotonda in presenza con pazienti, caregiver e medici, trasmessa in tutto il mondo tramite webcast. Sarà incentrata sulle esperienze dei pazienti, il peso della malattia e la necessità di nuove opzioni terapeutiche. Gli interessati possono registrarsi su www.RRPAwareness.org.
Precigen (PGEN) y la Fundación de Papilomatosis Respiratoria Recurrente (RRPF) anunciaron que coorganizarán el Día de Concienciación sobre RRP anual el 11 de junio de 2025 en Washington DC. Este evento internacional tiene como objetivo aumentar la conciencia sobre la papilomatosis respiratoria recurrente (RRP), una enfermedad crónica rara que afecta tanto a niños como a adultos.
La RRP, causada principalmente por la infección de VPH 6/11, provoca el crecimiento de papilomas en las vías respiratorias, causando alteraciones en la voz, obstrucción de las vías aéreas y posibles neumonías post-obliterativas. La enfermedad afecta aproximadamente a 27,000 adultos en EE.UU. y a más de 125,000 pacientes en todo el mundo. Actualmente no existe un tratamiento aprobado por la FDA, y los pacientes requieren múltiples cirugías a lo largo de su vida.
El evento contará con una mesa redonda presencial con pacientes, cuidadores y médicos, transmitida globalmente vía webcast. Se centrará en las experiencias de los pacientes, la carga de la enfermedad y la necesidad de nuevas opciones de tratamiento. Los interesados pueden registrarse en www.RRPAwareness.org.
Precigen (PGEN)과 재발성 호흡기 유두종증 재단(RRPF)은 2025년 6월 11일 워싱턴 DC에서 연례 RRP 인식의 날을 공동 주최한다고 발표했습니다. 이 국제 행사는 어린이와 성인 모두에게 영향을 미치는 희귀 만성 질환인 재발성 호흡기 유두종증(RRP)에 대한 인식을 높이는 것을 목표로 합니다.
RRP는 주로 HPV 6/11 감염에 의해 발생하며, 호흡기 내 유두종 성장으로 인해 음성 장애, 기도 폐쇄, 그리고 폐쇄 후 폐렴을 유발할 수 있습니다. 이 질환은 미국 내 약 27,000명의 성인 환자와 전 세계적으로 125,000명 이상의 환자에게 영향을 미칩니다. 현재 FDA 승인 치료법이 없어 환자들은 평생 여러 차례 수술을 받아야 합니다.
이번 행사는 환자, 보호자, 의사와 함께하는 대면 패널 토론을 포함하며, 전 세계에 웹캐스트로 방송될 예정입니다. 환자 경험, 질병 부담, 새로운 치료 옵션의 필요성에 초점을 맞출 것입니다. 관심 있는 분들은 www.RRPAwareness.org에서 등록할 수 있습니다.
Precigen (PGEN) et la Recurrent Respiratory Papillomatosis Foundation (RRPF) ont annoncé qu'ils co-organiseront la journée annuelle de sensibilisation RRP Awareness Day le 11 juin 2025 à Washington DC. Cet événement international vise à sensibiliser à la papillomatose respiratoire récurrente (RRP), une maladie chronique rare touchant enfants et adultes.
La RRP, principalement causée par une infection au HPV 6/11, entraîne la formation de papillomes dans les voies respiratoires, provoquant des troubles de la voix, une obstruction des voies aériennes et des pneumonies post-obstructives potentielles. La maladie affecte environ 27 000 adultes aux États-Unis et plus de 125 000 patients dans le monde. Actuellement, aucun traitement approuvé par la FDA n'existe, les patients nécessitant plusieurs interventions chirurgicales au cours de leur vie.
L'événement comprendra une table ronde en présentiel avec des patients, des aidants et des médecins, diffusée mondialement via webcast. Elle se concentrera sur les expériences des patients, le fardeau de la maladie et le besoin de nouvelles options thérapeutiques. Les personnes intéressées peuvent s'inscrire sur www.RRPAwareness.org.
Precigen (PGEN) und die Recurrent Respiratory Papillomatosis Foundation (RRPF) gaben bekannt, dass sie am 11. Juni 2025 in Washington DC gemeinsam den jährlichen RRP Awareness Day veranstalten werden. Die internationale Veranstaltung soll das Bewusstsein für die rezidivierende respiratorische Papillomatose (RRP) schärfen, eine seltene chronische Erkrankung, die sowohl Kinder als auch Erwachsene betrifft.
RRP, hauptsächlich verursacht durch eine HPV 6/11-Infektion, führt zu Papillomen in den Atemwegen, was Stimmstörungen, verengte Atemwege und mögliche postobstruktive Pneumonien zur Folge hat. Die Krankheit betrifft etwa 27.000 erwachsene Patienten in den USA und über 125.000 weltweit. Derzeit gibt es keine von der FDA zugelassene Behandlung, und die Patienten benötigen im Laufe ihres Lebens mehrere Operationen.
Die Veranstaltung umfasst eine Podiumsdiskussion vor Ort mit Patienten, Betreuern und Ärzten, die weltweit per Webcast übertragen wird. Im Fokus stehen Patientenerfahrungen, die Krankheitslast und der Bedarf an neuen Behandlungsmöglichkeiten. Interessierte können sich unter www.RRPAwareness.org anmelden.
- None.
- None.
– International event will raise awareness and bring together RRP patients, caregivers, and the healthcare community supporting them –
– Recurrent respiratory papillomatosis is a rare, debilitating, chronic disease that impacts both children and adults and is mainly driven by HPV 6/11 infection –
– There is no FDA-approved therapeutic for the treatment of RRP, and the current standard-of-care is repeated surgeries, which do not address the underlying cause of disease and are associated with significant morbidity and risk of irreversible injury –
RRP impacts both children and adults and is mainly driven by HPV 6/11 infection resulting in papilloma growth in the upper and lower respiratory tract, potentially leading to severe voice disturbance, compromised airway, and recurrent post-obstructive pneumonias. Although rare, RRP has the potential for transformation to malignant cancer and can be fatal. Current estimates suggest there are approximately 27,000 adult patients in the US and more than 125,000 patients outside of the US. There is no cure for RRP and the current standard-of-care is repeated surgeries, which do not address the underlying cause of disease and are associated with significant morbidity. With the cycle of recurrence and surgery, patients can require hundreds of lifetime surgeries. The cumulative risk of iatrogenic laryngeal injury increases with each RRP surgery, particularly with patients requiring five or more lifetime surgeries. There is high unmet need for a treatment option that can treat the underlying cause of the disease and reduce the need for RRP surgeries.
RRP Awareness Day activities will culminate in a live event on June 11th in
"As a rare and chronic disease, a collective voice is needed to support the RRP patient community. This event provides an important platform for our community to help raise awareness about the experience and burden of living with a rare, chronic and debilitating disease like RRP," said Kim McClellan, Board President, RRPF. "We encourage anyone living with RRP, either as a patient, family member or caregiver, to join us to support our community."
"Building on last year's successful inaugural RRP Awareness Day, we are proud to join RRPF again to co-host this extraordinary event in a potentially game-changing year for RRP patients. For too long, the RRP community has lived without hope for a treatment that addresses the underlying cause of disease and without true recognition of the devastating nature of this disease. Instead, they have endured ongoing daily burdens to their lives coupled with endless surgeries, which carry tremendous risk for irreversible injury and other morbidities. With new research and innovations, we believe that hope is on the horizon and we invite you to join us on June 11th to support the RRP community," said Helen Sabzevari, PhD, President and CEO of Precigen.
To stay up-to-date with RRP Awareness Day activities and to register for the June 11th webcast, please visit www.RRPAwareness.org.
Precigen: Advancing Medicine with Precision®
Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward clinical proof-of-concept and commercialization. For more information about Precigen, visit www.precigen.com or follow us on LinkedIn or YouTube.
About RRPF
The Recurrent Respiratory Papillomatosis Foundation (RRPF) was created to provide family support; promote public awareness; and aid in the prevention, cure, and treatment of recurrent respiratory papillomatosis (RRP), a rare disease that affects the voice. The most common symptoms of RRP are a hoarse or strained voice, dysphonia (difficulty in speaking), or aphonia (loss of voice). The organization focuses primarily on networking within the RRP community, including patients, families, medical practitioners, and researchers. Its goal is to stimulate more RRP-related research that may lead to more effective treatments and, ultimately, a cure for this disease.
Investor Contact:
Steven M. Harasym
Tel: +1 (301) 556-9850
investors@precigen.com
Media Contact:
Donelle M. Gregory
press@precigen.com
View original content:https://www.prnewswire.com/news-releases/precigen-and-recurrent-respiratory-papillomatosis-foundation-to-host-the-2025-international-rrp-awareness-day-on-june-11th-302429969.html
SOURCE Precigen, Inc.
FAQ
What is the significance of the June 11, 2025 RRP Awareness Day event hosted by Precigen (PGEN)?
How many patients are affected by RRP according to Precigen's (PGEN) latest data?
What are the current treatment options for RRP patients discussed in Precigen's (PGEN) announcement?
What are the main symptoms and complications of RRP mentioned in Precigen's (PGEN) release?
How can interested participants join the 2025 RRP Awareness Day event by Precigen (PGEN)?
